AGF Management Ltd. Acquires 76,464 Shares of Pfizer Inc. (NYSE:PFE)

AGF Management Ltd. increased its holdings in Pfizer Inc. (NYSE:PFE) by 6.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,223,841 shares of the biopharmaceutical company’s stock after purchasing an additional 76,464 shares during the quarter. AGF Management Ltd.’s holdings in Pfizer were worth $34,243,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of PFE. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in Pfizer during the fourth quarter valued at $16,166,000. LGT Group Foundation raised its holdings in shares of Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after purchasing an additional 18,274 shares during the period. First Heartland Consultants Inc. raised its holdings in shares of Pfizer by 43.3% during the fourth quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 3,933 shares during the period. ORG Partners LLC raised its holdings in shares of Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 44,458 shares during the period. Finally, Kempner Capital Management Inc. acquired a new position in shares of Pfizer during the first quarter valued at about $2,439,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PFE shares. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Stock Down 0.3 %

Pfizer stock opened at $29.64 on Thursday. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $34.62. The firm has a 50 day moving average price of $29.16 and a 200-day moving average price of $28.09. The company has a market capitalization of $167.96 billion, a P/E ratio of -494.00, a P/E/G ratio of 1.00 and a beta of 0.68. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.67%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.